Bruker Corporation (Nasdaq: BRKR), a provider of high performance scientific instruments and high value analytical and diagnostic solutions, announced on Monday that it has launched the Dimension Nexus atomic force microscope (AFM), marking a new standard in cost-effective, large-sample AFM systems.
Revealed on 19 December 2023 at the 2024 MRS Fall Meeting, Dimension Nexus expands the company's renowned Dimension product line, which boasts over 4,600 global installations. Equipped with the advanced NanoScope 6 controller, it offers seamless access to Bruker's proprietary PeakForce Tapping technology and over 50 specialised AFM modes, targeting growing laboratories and multi-user facilities.
Designed with low noise, low drift and open architecture, Dimension Nexus combines high performance with affordability. Its NanoScope 6 controller enhances productivity, while exclusive features like ScanAsyst simplify operations. The system supports advanced modes including AFM-nDMA for viscoelastic analysis and PeakForce QNM for mechanical property mapping. A programmable stage further enables high-throughput, multi-site analysis, making it a versatile solution for cutting-edge research.
Bruker Corporation continues to innovate in post-genomic scientific instrumentation, supporting breakthroughs in life sciences, nanoanalysis and advanced semiconductor research.
Eli Lilly's Omvoh receives US FDA approval
Axcynsis Therapeutics' IND for AT03-65 receives US FDA approval
Innovent Biologics' IBI343 receives Breakthrough Therapy Designation in China
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Johnson & Johnson submits New Drug Application for TAR-200 to treat bladder cancer
GenSight Biologics reports positive five-year results for LUMEVOQ gene therapy in LHON Patients
Futura Medical plc reports positive results from WSD4000 Home User Study
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Sen-Jam Pharmaceutical receives ethics approval for Australian clinical trial of SJP-001
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
Kelker Pharma introduces NUTRILINQ for patients using weight loss drugs
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
BioArctic reports FDA acceptance of BLA for for subcutaneous maintenance dosing of Leqembi
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing